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Ion Gresser, a virologist who transformed understanding of the roles of interferons, may be best remembered for showing 
that in mice, interferon-α (IFN-α) can 
produce acute and chronic disease. At the 
time Gresser began these studies, interferon 
was considered to be a selective antiviral 
substance, harmless to uninfected cells and 
organisms, and there was no indication that 
cytokines would play a role in pathogenesis. 
That belief was shattered with the 1975 
Nature publication with the simple title 
“Lethality of interferon preparations for 
newborn mice.”
Gresser subsequently demonstrated 
that antibodies to IFN-α can protect young 
mice from death caused by infection with 
lymphocytic choriomeningitis virus. This 
study can be considered a stepping-stone 
for the therapeutic application of antibodies 
to cytokines in the treatment of human 
disease, which was introduced much later 
and revolutionized the management of some 
autoimmune diseases.
Since its first description by Alick Isaacs 
and Jean Lindenmann in 1957, interferon 
was believed to be important in an 
organism’s resistance to viral infection and 
was thought to have the potential to become 
as useful in the treatment of viral diseases as 
penicillin and other antibiotics had turned 
out to be for infections caused by bacteria. 
Gresser made substantial contributions to 
the body of knowledge about interferon 
that is now taken for granted. His early 
studies of mouse models of viral infections 
established that injections of IFN-α can 
indeed protect mice from viral infection. 
Gresser was among the first investigators to 
explore the potential of interferons in the 
control of malignancies in animal models, 
showing that it can protect mice not only 
from leukemias caused by viruses but also 
from solid tumors and metastatic cancer. 
Those findings contributed to the original 
optimism about the potential usefulness 
of interferons not only in the treatment of 
viral infections but also in the control of 
cancer in humans. Unfortunately, those 
expectations were generally not borne out 
by later clinical trials. Although interferon 
therapies would show moderate efficacy in 
the control of some viral infections, such as 
chronic active infection with hepatitis virus 
B or C, and even more modest results in 
some malignancies, the benefits fell short of 
the initial expectations.
More surprising at the time was the first 
demonstration, by Gresser and colleagues 
in 1973, that IFN-α enhances the expression 
of histocompatibility antigens and modifies 
the surface of uninfected cells, and that 
it has other immunomodulatory actions. 
Those last findings were among the first 
demonstrations that interferons have actions 
separate from their antiviral activities and 
broadened the scope of interferon research.
A native of New York City, Gresser 
developed early on an appreciation of 
science and the arts. His mother, Gisela 
Kahn Gresser, was a classicist and 
prominent chess player who dominated 
women’s chess for more than three decades, 
winning nine national titles between 1944 
and 1969. His father, William Gresser, 
a successful attorney, moonlighted as a 
serious musicologist. Ion Gresser — who 
too retained a life-long passion for the 
piano and classical music — completed his 
undergraduate studies at Harvard University. 
In addition to science, he was interested in 
history, European literature and Russian.
After his graduation from Yale School 
of Medicine and an internship at Bellevue 
Hospital in New York City, he joined the 
army and served as head of an infectious 
disease laboratory at the army post in Camp 
Zama, Japan. There he developed an active 
interest in virology and published his first 
papers on Japanese encephalitis and Asian 
flu — a passion that blossomed during a 
postdoctoral fellowship in the laboratory of 
John F. Enders, the Harvard-based virologist 
and co-recipient of the 1954 Nobel Prize in 
physiology or medicine. While working in 
Enders’ lab, Gresser also published his first 
paper devoted to interferons.
A Francophile, Gresser moved to Paris in 
the early 1960s, first joining the laboratory 
of another interferon pathfinder, Charles 
Chany, at the Hôpital St. Vincent de Paul, 
and soon thereafter establishing his own 
laboratory at the Institut de Recherches 
Scientifiques sur le Cancer in Villejuif, 
outside Paris. Eventually, Gresser ended up 
spending decades at the Villejuif laboratory, 
and it was there that he conducted all of 
his many original studies for which he 
became known. Although he retired from 
his position at Villejuif many years ago, 
he continued to publish reviews, as well 
as original research in collaboration with 
others. His very last paper, co-authored with 
Pierre Lebon, Yanick Crow and Jean-Laurent 
Casanova, appeared in March of this year, 
only weeks before his passing.
Arguably, the most important 
contribution of Gresser and his colleagues 
was the demonstration of harmful effects 
of interferons in animal models, as well 
as the clear evidence that interferons 
contribute to pathogenesis, including the 
pathogenesis of viral infections. Among 
the most surprising discoveries was 
that injection of mice with potent sheep 
immunoglobulin directed against IFN-α 
markedly inhibits the manifestations 
of disease caused by infection with 
lymphocytic choriomeningitis virus 
(weight loss, liver-cell necrosis and death), 
despite the fact that the treated mice had 
100-fold more of the virus in their serum 
than did mice that were not treated with 
the anti-interferon immunoglobulin. At 
the time of their publication in 1977, 
these findings not only were completely 
unexpected and counterintuitive but 
also presaged the advent of the dramatic 
beneficial effects of anti-cytokine therapies 
in humans, such as those achieved with 
the use of monoclonal antibodies to the 
cytokine TNF in the treatment rheumatoid 
arthritis, Crohn’s disease and some other 
autoimmune disorders. This discovery 
alone would be sufficient to earn Ion 
Gresser a lasting abode in the pantheon  
of medical science. ❐
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